# A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

> **NCT04855929** · PHASE1 · COMPLETED · sponsor: **Anaveon AG** · enrollment: 55 (actual)

## Conditions studied

- Advanced Solid Tumor
- Adult Disease
- Lung Cancer

## Interventions

- **DRUG:** ANV419
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04855929
- **Lead sponsor:** Anaveon AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-25
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04855929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04855929, "A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04855929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*